Fairvalue-Calculator Fairvalue-Calculator
EN DE

Roivant Sciences Ltd (ROIV) Fair Value & Analysis

Healthcare · US · Market cap $20.2B

Price$32.21
Fair Value$28.32
Upside-12.1%
Quality82/100
Evidence: Low Range $21.24 – $35.41

Fair value as of: Jun 24, 2026

Analysis

Roivant Sciences Ltd (ROIV) currently trades at $32.21, while our model-based Fair Value estimate is $28.32 — implying the stock looks roughly 12.1% overvalued today. We read business quality at 82/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Roivant Sciences Ltd (ROIV) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $28.32 versus a price of $32.21 — about −12% (overvalued). Model-based estimate, not financial advice.
What is the fair value of ROIV?
Our 21-model fair value for Roivant Sciences Ltd is $28.32 (as of Jun 24, 2026), built from audited fundamentals. The current price is $32.21.
What is the quality score of ROIV?
Roivant Sciences Ltd has a Quality Score of 82/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.